Atea Pharmaceuticals AVIR
Atea Pharmaceuticals reported a net loss of $32.16 million for the three months ended Sep 30, 2026.
Atea Pharmaceuticals (AVIR) filed a 10-Q with the SEC on Nov 9, 2026, 5:02 pm ET. Source: the filing on SEC EDGAR.
- Form
- 10-Q
- Filed
- Importance
- Notable
- Accession
- 0001193125-26-453807
- Net loss: $32.16 million for the three months ended Sep 30, 2026
- Diluted EPS: -$0.40 for the three months ended Sep 30, 2026
- Cash and equivalents: $97.92 million at Sep 30, 2026
Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.
